Cyclophosphamide enhances human tumor growth in nude rat xenografted tumor models

Neoplasia

Volumn 11, Issue 2, 2009, Pages 187-195

  Wu, Yingjen Jeffrey ^a   Muldoon, Leslie L ^a,b   Dickey, Dana Thomas ^a   Lewin, Seth J ^a   Varallyay, Csanad G ^a   Neuwelt, Edward A ^a,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; CD68 ANTIGEN; CYCLOPHOSPHAMIDE; GLUTATHIONE; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CANCER; BRAIN METASTASIS; CANCER CELL; CONTROLLED STUDY; FEMALE; HEMISPHERE; HUMAN; HUMAN CELL; INTERNAL CAROTID ARTERY; LEUKOCYTE COUNT; LUNG CARCINOMA; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 61349137623     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.81352     Document Type: Article

References (46)

1. Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, Hicklin DJ, Chaplin D, Foster FS, Benezra R, et al. (2006). Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313, 1785-1787.
2. Munoz R, Man S, Shaked Y, Lee CR, Wong J, Francia G, and Kerbel RS (2006). Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res 66, 3386-3391.
3. Malik SW, Myers JL, DeRemee RA, and Specks U (1996). Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med 154, 1851-1856.
4. Bernard-Marty C, Mano M, Paesmans M, Accettura C, Munoz-Bermeo R, Richard T, Kleiber K, Cardoso F, Lobelle JP, Larsimont D, et al. (2003). Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of nodepositive breast cancer patients. Ann Oncol 14, 693-698.
5. Stein JP, Skinner EC, Boyd SD, and Skinner DG (1993). Squamous cell carcinoma of the bladder associated with cyclophosphamide therapy for Wegener's granulomatosis: a report of 2 cases. J Urol 149, 588-589.
6. Stillwell TJ, Benson RC Jr, DeRemee RA, McDonald TJ, and Weiland LH (1988). Cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis. Arthritis Rheum 31, 465-470.
7. Dore JF, Bailly M, and Bertrand S (1987). Metastases of human tumors in experimental animals. Anticancer Res 7, 997-1003.
8. Kamb A (2005). What's wrong with our cancer models? Nat Rev Drug Discov 4, 161-165.
9. Ikeda K, Ichikawa T, Wakimoto H, Silver JS, Deisboeck TS, Finkelstein D, Harsh GRT, Louis DN, Bartus RT, Hochberg FH, et al. (1999). Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 5, 881-887.
10. Kambara H, Saeki Y, and Chiocca EA (2005). Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus. Cancer Res 65, 11255-11258.
11. Fulci G, Breymann L, Gianni D, Kurozomi K, Rhee SS, Yu J, Kaur B, Louis DN, Weissleder R, Caligiuri MA, et al. (2006). Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci USA 103, 12873-12878.
12. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, and Sabzevari H (2005). Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105, 2862-2868.
13. Motoyoshi Y, Kaminoda K, Saitoh O, Hamasaki K, Nakao K, Ishii N, Nagayama Y, and Eguchi K (2006). Different mechanisms for anti-tumor effects of lowand high-dose cyclophosphamide. Oncol Rep 16, 141-146.
14. Honeychurch J, Glennie MJ, and Illidge TM (2005). Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells. Cancer Res 65, 7493-7501.
15. Yamauchi K, Yang M, Hayashi K, Jiang P, Yamamoto N, Tsuchiya H, Tomita K, Moossa AR, Bouvet M, and Hoffman RM (2008). Induction of cancer metastasis by cyclophosphamide pretreatment of host mice: an opposite effect of chemotherapy. Cancer Res 68, 516-520.
16. van Putten LM, Kram LK, van Dierendonck HH, Smink T, and Fuzy M (1975). Enhancement by drugs of metastatic lung nodule formation after intravenous tumour cell injection. Int J Cancer 15, 588-595.
17. Kline I, Gang M, Tyrer DD, Mantel N, Venditti JM, and Goldin A (1968). Duration of drug levels in mice as indicated by residual antileukemic efficacy. Chemotherapy 13, 28-41.
18. Fruehauf JP and Meyskens FL Jr (2007). Reactive oxygen species: a breath of life or death? Clin Cancer Res 13, 789-794.
19. Cao Y (2005). Tumor angiogenesis and therapy. Biomed Pharmacother 59 (Suppl 2), S340-S343.
20. Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, and Ribatti D (2006). Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 13, 1845-1857.
21. Neuwelt EA, Pagel MA, Kraemer DF, Peterson DR, and Muldoon LL (2004). Bone marrow chemoprotection without compromise of chemotherapy efficacy in a rat brain tumor model. J Pharmacol Exp Ther 309, 594-599.
22. Soussain C, Muldoon LL, Varallyay C, Jahnke K, DePaula L, and Neuwelt EA (2007). Characterization and magnetic resonance imaging of a rat model of human B-cell central nervous system lymphoma. Clin Cancer Res 13, 2504-2511.
23. Anton E (1997). Ultrastructural changes of stromal cells of bone marrow and liver after cyclophosphamide treatment in mice. Tissue Cell 29, 1-9.
24. Nygaard UC and Lovik M (2002). Blood and spleen lymphocytes as targets for immunotoxic effects in the rat-a comparison. Toxicology 174, 153-161.
25. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, and Chauffert B (2007). Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56, 641-648.
26. Pollard JW (2004). Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4, 71-78.
27. Condeelis J and Pollard JW (2006). Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124, 263-266.
28. Woodfin A, Voisin MB, andNourshargh S (2007). PECAM-1: a multi-functional molecule in inflammation and vascular biology. Arterioscler Thromb Vasc Biol 27, 2514-2523.
29. Kalinowska A and Losy J (2006). PECAM-1, a key player in neuroinflammation. Eur J Neurol 13, 1284-1290.
30. Park HJ, Kim MN, Kim JG, Bae YH, Bae MK, Wee HJ, Kim TW, Kim BS, Kim JB, Bae SK, et al. (2007). Up-regulation of VEGF expression by NGF that enhances reparative angiogenesis during thymic regeneration in adult rat. Biochim Biophys Acta 1773, 1462-1472.
31. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, and Folkman J (2000). Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60, 1878-1886.
32. Mauro E, Rigolin GM, Fraulini C, Sofritti O, Ciccone M, De Angeli C, Castoldi G, and Cuneo A (2007). Mobilization of endothelial progenitor cells in patients with hematological malignancies after treatment with filgrastim and chemotherapy for autologous transplantation. Eur J Haematol 78, 374-380.
33. Ribatti D (2004). The involvement of endothelial progenitor cells in tumor angiogenesis. J Cell Mol Med 8, 294-300.
34. Dineen SP, Lynn KD, Holloway SE, Miller AF, Sullivan JP, Shames DS, Beck AW, Barnett CC, Fleming JB, and Brekken RA (2008). Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice. Cancer Res 68, 4340-4346.
35. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, et al. (2001). Impaired recruitment of bone-marrow- derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7, 1194-1201.
36. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, Fuks Z, and Kolesnick R (2003). Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300, 1155-1159.
37. Goon PK, Lip GY, Boos CJ, Stonelake PS, and Blann AD (2006). Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia 8, 79-88.
38. Iwamoto Y, Fujita Y, and Sugioka Y (1992). YIGSR, a synthetic laminin peptide, inhibits the enhancement by cyclophosphamide of experimental lung metastasis of human fibrosarcoma cells. Clin Exp Metastasis 10, 183-189.
39. Carmel RJ and Brown JM (1977). The effect of cyclophosphamide and other drugs on the incidence of pulmonary metastases in mice. Cancer Res 37, 145-151.
40. Manda K and Bhatia AL (2003). Prophylactic action of melatonin against cyclophosphamide-induced oxidative stress in mice. Cell Biol Toxicol 19, 367-372.
41. Abraham P and Sugumar E (2008). Increased glutathione levels and activity of PON1 (phenyl acetate esterase) in the liver of rats after a single dose of cyclophosphamide: a defense mechanism? Exp Toxicol Pathol 59, 301-306.
42. Lopez SG and Luderer U (2004). Effects of cyclophosphamide and buthionine sulfoximine on ovarian glutathione and apoptosis. Free Radic BiolMed 36, 1366-1377.
43. Hosseinimehr SJ and Karami M (2005). Chemoprotective effects of captopril against cyclophosphamide-induced genotoxicity in mouse bone marrow cells. Arch Toxicol 79, 482-486.
44. Bakan N, Taysi S, Yilmaz O, Bakan E, Kuskay S, Uzun N, and Gundogdu M (2003). Glutathione peroxidase, glutathione reductase, Cu-Zn superoxide dismutase activities, glutathione, nitric oxide, and malondialdehyde concentrations in serum of patients with chronic lymphocytic leukemia. Clin Chim Acta 338, 143-149.
45. Silber R, Farber CM, Papadopoulos E, Nevrla D, Liebes L, Bruck M, Brown R, and Canellakis ZN (1992). Glutathione depletion in chronic lymphocytic leukemia B lymphocytes. Blood 80, 2038-2043.
46. Genka S, Deutsch J, Stahle PL, Shetty UH, John V, Robinson C, Rapoport SI, and Greig NH (1990). Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoramide mustard in the rat. Cancer Chemother Pharmacol 27, 1-7.